Fatal Case of Possible Thyroid Crisis Induced by SARS-CoV-2 Infection: A Case Report

Febriyani Hamzah,1 Andi Makbul Aman,2 Harun Iskandar3

1Department of Internal Medicine, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia
2Division of Metabolic Endocrine, Department of Internal Medicine, Faculty of Medicine, Hasanuddin University – Wahidin Sudirohusodo Hospital, Makassar, Indonesia
3Division of Pulmonology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia

Abstract

Thyroid crisis is an emergency due to impaired thyroid function caused by various conditions, particularly infections such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that result in the dysfunction of various vital organs. We report a case of a 31-year-old Indonesian female with a 2-year history of hyperthyroidism with elevated thyroid-stimulating hormone (TSH) receptor antibodies (TRAb) who developed thyroid crisis possibly in association with SARS-CoV-2 pneumonia, sepsis, and disseminated intravascular coagulation (DIC). Prior to admission, she was treated for her hyperthyroidism with propylthiouracil and had been in stable remission for a year. She was admitted to the Emergency Room with complaints of watery stools, icteric sclerae, jaundice, coughing, and shortness of breath. The physical examination showed a World Health Organization (WHO) performance score of 4, delirium, blood pressure within normal limits, tachycardia, tachypnea, axillary temperature of 36.7°C, icteric sclerae, jaundice, and exophthalmos. There was a 3 cm palpable nodule on the right side of the neck. Auscultation of the lungs revealed bilateral pulmonary rales. Abdominal examination noted a palpable liver and enlarged spleen. Laboratory tests showed thrombocytopenia, electrolyte imbalance, hypoalbuminemia and elevated transaminases. The thyroid function tests showed a suppressed TSH level with an elevated free thyroxine (FT4) level. The SARS-CoV-2 polymerase chain reaction (PCR) swab test was positive. Initial patient management was with supportive therapy that included favipiravir and anti-hyperthyroidism medication; however, despite these interventions, her condition continued to deteriorate and she died after a few hours. This case demonstrates no difference in therapy between patients with thyroid crises and COVID-19 or other infections. Proper and timely treatment is important for reducing mortality rates.

Key words: COVID-19, SARS CoV-2, thyrotoxic crisis, thyroid storm, thyrotoxicosis

INTRODUCTION

SARS-CoV-2 infection causes coronavirus disease 2019 (COVID-19) and pulmonary and systemic inflammation, leading to multi-organ dysfunction.1 Mortality increases due to respiratory failure and other complications such as cardiovascular failure and DIC, and also due to the presence of comorbidities such as autoimmune diseases that alter thyroid function (e.g., Graves’ disease [GD]) and COVID-19-associated thyroid disease, particularly with delayed diagnosis and management.2 Thyroid crises can be triggered by events such as surgery, infection, inadequate antithyroid drug (ATD) therapy, thyroid surgery trauma, or uncontrolled diabetes mellitus (DM), with upper respiratory tract infection (e.g., SARS-CoV-2 infection) being the second-most common cause.3,4 COVID-19 affects organs and organ systems, including the endocrine system, where the pituitary-thyroid axis is the direct or indirect target of SARS-CoV-2, which can cause central hypothyroidism. Thyroid dysfunction can be found in SARS-CoV-2 infected patients where COVID-19 causes thyroid hormone imbalance in proportion to the degree of infection.1,7

CASE

In July 2021, a 31-year-old Indonesian female with complaints of diarrhea of more than three times a day without mucus or blood was admitted to the emergency room. She reported fever and scleral icterus for the last three days. She had a history of hyperthyroidism since three days. She had a history of hyperthyroidism since 2019 with elevated TRAb of 4.02 IU/L (reference value ≤1.75 IU/L), currently in stable remission after one year of propylthiouracil. There was no history of surgery. She reported occasional nonproductive cough and shortness of breath but denied chest pain. She had no history of COVID-19 vaccination or contact with COVID-19 patients. Physical examination showed a WHO performance score...
hours later, the SARS-CoV-2 PCR swab result was positive with a threshold cycle (Cₜ) of 18.23 (reference Cₜ >38). Electrocardiogram showed sinus tachycardia at 125 beats/minute. Chest X-ray (CXR) reported a thyroid nodule on the right cervical area and bilateral pneumonia. A multi-slice computed tomography (MSCT) scan of the chest showed ground glass opacity on the posterior dorsal lung (Figure 1).

The patient had a Burch-Wartofsky Point Scale (BWPS) score of 75 (Table 2) which fulfills the criteria of thyroid storm. By the Japan Thyroid Association (JTA) thyroid storm criteria (Table 3), patient has definite thyroid storm (TS1). Admitting impression was sepsis-induced thyroid crisis due to COVID-19 infection and DIC. Initial patient management included monitoring vital signs (Figure 2), electrolyte correction, oxygen at 10 L/min via non-rebreathing mask, fluid resuscitation with acetate Ringer’s solution at 30 cc/kg of body weight every 3 h, 40 mg of omeprazole administered intravenously every 12 h, 40 mg of propranolol administered nasogastrically every 6 h, 8 mg of dexamethasone administered intravenously every 24 h, 5 Lugol drops administered nasogastrically every 6 h, 60 mg of methimazole administered nasogastrically every 24 h, 2 mg of diazepam administered intravenously every 24 h, and the planned subcutaneous administration of 0.4 cc of enoxaparin every 24 h. Pulmonology service prescribed favipiravir.

Six hours after admission, the patient complained of worsening shortness of breath and became unconscious with a GCS of 9 (E2M5V2) and average blood pressure of 125/65 mmHg, heart rate of 123 beats/minute, temperature of 37°C, respiratory rate of 26 times/minute, 96% oxygen saturation, and ineffective breathing pattern. She was ideally for transfer to the Intensive Care Unit (ICU); however, the

**Figure 1.** An axial non-contrast MSCT of the thorax showing minimal ground-glass opacities on the posterodorsal lung (arrow).

**Figure 2.** Vital signs of patient throughout admission.
hospital did not have an ICU for patients with COVID-19, and its laboratory could not perform diagnostic PCR tests for SARS-CoV-2 infection, delaying patient management. The patient died a few hours after the start of treatment.

Table 1. Clinical laboratory results

| Measure                        | Reference Interval | Result |
|-------------------------------|-------------------|--------|
| Leukocytes (per μL)           | 4,000–9,000       | 7,600  |
| Absolute neutrophil count (%) | 25.0–78.0         | 70.6   |
| Absolute lymphocyte count (%) | 17.0–57.0         | 16.3   |
| Absolute monocyte count (%)   | 0.0–10.0          | 8.8    |
| Absolute eosinophil count     | 0.0–10.0          | 3.3    |
| Absolute basophil count       | 0.0–2.0           | 3.0    |
| Erythrocytes (per μL)         | 3,760,000–5,700,000 | 3,700,000 |
| Platelet count (per μL)       | 150,000–350,000   | 60,000 |
| Hemoglobin (g/dL)             | 12.0–18.0         | 11.9   |
| Hematocrit (%)                | 33.5–52.0         | 35.8   |
| Sodium (mmol/L)               | 136–145           | 132.2  |
| Potassium (mmol/L)            | 3.5–5.1           | 3.1    |
| Chloride (mmol/L)             | 94–110            | 101    |
| Urea (mg/dL)                  | 6–4               | 15     |
| Creatinine (mg/dL)            | 0.5–1.3           | 0.9    |
| Albumin (g/dL)                | 3.7–5.3           | 3.1    |
| Random blood glucose (mg/dL)  | 70–140            | 110    |
| Alanine aminotransferase (U/L)| <41               | 200    |
| Aspartate aminotransferase (U/L)| <37              | 392    |

Table 2. The patient’s Burch and Wartofsky Point Scale (BWPS)

| Thermoregulatory dysfunction | Points |
|------------------------------|--------|
| Temperature (°F)             |        |
| 99–99.9                      | 5      |
| 100–100.9                    | 10     |
| 101–101.9                    | 15     |
| 102–102.9                    | 20     |
| 103–103.9                    | 25     |
| >104                         | 30     |

| Central nervous system effects | Points |
|--------------------------------|--------|
| Absent                         | 0      |
| Mild (agitation)               | 10     |
| Moderate (delirium, psychosis, or extreme lethargy) | 20   |
| Severe (seizure or coma)       | 30     |

| Gastrointestinal-hepatic dysfunction | Points |
|-------------------------------------|--------|
| Absent                              | 0      |
| Moderate (diarrhea, nausea/vomiting, or abdominal pain) | 10    |
| Severe (unexplained jaundice)       | 20     |

| Cardiovascular dysfunction | Points |
|----------------------------|--------|
| Tachycardia (beats/min)    |        |
| 90–109                     | 5      |
| 110–119                    | 10     |
| 120–129                    | 15     |
| 130–139                    | 20     |
| >140                       | 25     |
| Atrial fibrillation         | 10     |

| Congestive heart failure | Points |
|-------------------------|--------|
| Absent                  | 0      |
| Mild (pedal edema)      | 5      |
| Moderate (biphasal rales)| 10    |
| Severe (pulmonary edema)| 15     |

| Precipitating history | Points |
|----------------------|--------|
| Positive             | 0      |
| Negative             | 10     |

| Total Score | Points |
|-------------|--------|
| 75          | Thyroid Storm |

Discrimination criteria:

Prerequisite for diagnosis is presence of thyrotoxicosis with elevated levels of free triiodothyronine (FT3) or free thyroxine (FT4)

Symptoms

1. Central nervous system (CNS) manifestations: Restlessness, delirium, mental aberration/psychosis, somnolence/lethargy, coma (≥1 on the Japan Coma Scale or ≤14 on the Glasgow Coma Scale)
2. Fever: ≥38°C
3. Tachycardia: ≥130 beats/minute or heart rate ≥130 in atrial fibrillation
4. Congestive heart failure (CHF): Pulmonary edema, moist rales over more than half the lung field, cardiogenic shock, or Class IV by the New York Heart Association or ≤ Class III in the Killip classification
5. Gastrointestinal (GI)/hepatic manifestations: nausea, vomiting, diarrhea, or a total bilirubin level ≥3.0 mg/dL

Thyroid Storm Diagnosis Grade adapted from Akamizu, et al.:

TS1 (First combination): Thyrotoxicosis and at least one CNS manifestation and fever, tachycardia, CHF, or GI/hepatic manifestation
TS2 (Alternate combination): Thyrotoxicosis and at least one CNS manifestation and fever, tachycardia, CHF, or GI/hepatic manifestation

Exclusion and provisions

Cases are excluded if other underlying diseases clearly cause any of the following symptoms: fever (e.g., pneumonia and malignant hyperthermia), impaired consciousness (e.g., psychiatric disorders and cerebrovascular disease), CHF (e.g., acute myocardial infarction), and liver disorders (e.g., viral hepatitis and acute liver failure). Therefore, when it is difficult to determine whether the symptom is caused by TS or is simply a manifestation of an underlying disease, it should be regarded as being due to TS caused by these precipitating factors. Clinical judgment in this matter is required.

DISCUSSION

In this case report, the patient was diagnosed with thyroid storm consistent with the BWPS for thyrotoxicosis and the 2016 JTA and Japanese Endocrine Society criteria for thyroid storm. Thyroid crisis is a life-threatening condition often triggered by acute conditions or mental stress, developing into thyrotoxicosis and manifesting as multi-organ failure (MOF), with a reported 10.7% mortality rate in Japan. The thyroid crisis was triggered in this patient by SARS-CoV-2 infection in July 2021, at the peak of the second wave of COVID-19 infections in Indonesia.

Chen et al., studied 50 patients with confirmed COVID-19 infections, finding that 56% had abnormal TSH values, with low TSH associated with poor prognosis. In Indonesia in July 2021, 88,659 of 3,287,727 patients with confirmed COVID-19 died. The THYRCOV study by Lania et al., reported thyroid function changes in response to COVID-19 infection. Of their 287 patients, 31 had thyrotoxicosis (20.2%) and 15 had hypothyroidism (5.2%). Moreover, they found a significant relationship between increased interleukin 6 levels and decreased TSH, causing thyrotoxicosis, more severe systemic inflammation, and lower free-triiodothyronine (FT3) levels.

The pathological mechanism of changes in thyroid hormones in patients with SARS-CoV-2 infection occurs via direct viral mechanisms and angiotensin-converting enzyme 2 (ACE2) in the pituitary gland, which indirectly impacts systemic effects by activating proinflammatory

Table 3. The Japan Thyroid Association thyroid storm (TS) criteria

| Symptom                  | TS1 | TS2 |
|--------------------------|-----|-----|
| Fever                    |     |     |
| Tachycardia (≥130 bpm)   |     |     |
| Atrial fibrillation      |     |     |
| Congestive heart failure |     |     |
| Thyroid crisis           |     |     |

Thyroid Storm Diagnosis Grade adapted from Akamizu, et al:

TS1 (First combination): Thyrotoxicosis and at least one CNS manifestation and fever, tachycardia, CHF, or GI/hepatic manifestation
TS2 (Alternate combination): Thyrotoxicosis and at least one CNS manifestation and fever, tachycardia, CHF, or GI/hepatic manifestation

Exclusion and provisions

Cases are excluded if other underlying diseases clearly cause any of the following symptoms: fever (e.g., pneumonia and malignant hyperthermia), impaired consciousness (e.g., psychiatric disorders and cerebrovascular disease), CHF (e.g., acute myocardial infarction), and liver disorders (e.g., viral hepatitis and acute liver failure). Therefore, when it is difficult to determine whether the symptom is caused by TS or is simply a manifestation of an underlying disease, it should be regarded as being due to TS caused by these precipitating factors. Clinical judgment in this matter is required.

TS1, “Definite” TS; TS2, “Suspected” TS.
COVID-19 patients have hepatocellular damage caused by SARS-CoV-2 infection via ACE2 receptor expression. ACE2 expression in cholangiocyte cells causes cholestasis and cytokine storm conditions, increasing liver damage and hepatobiliary complications. While acute liver failure in thyroid storm is associated with increased FT3 due to mitochondrial apoptosis in hepatocytes, the pathologic mechanism for thyrotoxicosis is secondary ischemic hepatitis due to peripheral vasodilation and excessive thyroid hormone release due to acute heart failure.

In this patient, diarrhea and jaundice were manifestations of a thyroid crisis.

Thyroid crisis triggered by SARS-CoV-2 infection causes coagulopathy due to increased pulmonary platelet consumption, intravascular coagulation, and microangiopathic thrombosis. Coagulopathy is caused by systemic inflammation and SARS-CoV-2-specific mechanisms that cause endothelial dysfunction. When clinicians are aware of coagulation disorders in patients with SARS-CoV-2 infection, they should perform D-dimer, prothrombin time, and fibrinogen tests to assess their DIC scores. DIC events can be triggered by thrombocytopenia in patients with thyroid crisis and SARS-CoV-2 infection and, in turn, increase the risk of venous thromboembolism (e.g., pulmonary embolism and cerebral venous thrombosis) and stroke due to arterial thrombosis and embolism that causes atrial fibrillation. Low molecular weight heparin (LWMH) can be given as thromboprophylaxis, particularly in severe and critically ill patients. It has anticoagulant properties but can also limit viral entry into cells by interacting with the SARS-CoV-2 spike protein, decreasing heparinase activity, preventing plasma leakage, and neutralizing cytokines via other biological activities. It is preferable to look for contraindications and measure bleeding and venous thromboembolism risk using the IMPROVE and PADUA scores when providing anticoagulants as thromboprophylaxis. In this patient, the IMPROVE score was 2.5 (<7 indicates a low bleeding risk), and the PADUA score was 0 (<4 indicates a low venous thromboembolism risk). Therefore, we planned to administer 0.4cc/subcutaneous enoxaparin.

The Brazilian Society of Endocrinology and Metabolism and the THYRCOV study reported that thyroid dysfunction management during the COVID-19 pandemic was the same in patients with thyroid storm and co-infection with SARS-CoV-2 or other pathogens. They found that 16% of patients with SARS-CoV-2 infection treated for thyrotoxicosis experienced a two-fold greater thromboembolic event, an increased incidence of atrial fibrillation with suppressed TSH, and a higher mortality rate. The treatment of hyperthyroidism caused by GD in the current phase of the COVID-19 pandemic can be divided into two scenarios: (1) treatment of patients with a prior diagnosis of GD and on regular treatment with anti-thyroid drugs (ATDs); (2) treatment of patients with recently diagnosed GD who have not yet started therapy.

Our patient belongs to the first scenario. At the current stage of the COVID-19 pandemic, when face-to-face consultations can be difficult, it is especially important not to interrupt ATD treatment since any relapse would require an urgent medical appointment and increase the risk of complications (e.g., thyroid storm), which can be triggered by infections such as COVID-19. In general, ATD treatment is maintained for 12–24 months, after which the medication can be suspended. Alternatively, prolonged use of low-dose ATDs may be considered since it is safe and may increase the chance of Graves’ Disease remission. During the COVID-19 pandemic, telemedicine may be an alternative to manage patients with hyperthyroidism, and those with thyroid storm should be treated in infection centers with ICUs.

In the second scenario (patients with a recent GD diagnosis), ATDs should be the first therapeutic option due to possible current restrictions on nuclear medicine or surgical treatment. Surgical treatment should be performed in the rare circumstance of a patient not responding satisfactorily to ATDs, developing severe side effects to ATDs, or being unable to undergo radioiodine therapy.

In our patient, we provided supportive therapy by providing oxygen, installing a heart monitor, nasogastric tube, and urinary catheter, and giving crystalloid fluid up to 28 drops/minute. We planned to transfer the patient to the ICU when she was started to develop hemodynamic instability, had DIC and Multiorgan failure (MOF) and an APACHE score >9 (based on 2016 JTA criteria) but the hospital where she was admitted in had no ICU for patients with COVID-19.

Our case report highlights the importance of educating patients with thyroid disorders during the COVID-19 pandemic. Patients with GD should not discontinue their drugs (ATDs); (2) treatment of patients with recently diagnosed GD who have not yet started therapy. ATD treatment since any relapse would require an urgent medical appointment and increase the risk of complications (e.g., thyroid storm), which can be triggered by infections such as COVID-19. In general, ATD treatment is maintained for 12–24 months, after which the medication can be suspended. Alternatively, prolonged use of low-dose ATDs may be considered since it is safe and may increase the chance of Graves’ Disease remission. During the COVID-19 pandemic, telemedicine may be an alternative to manage patients with COVID-19.

Our case report highlights the importance of educating patients with thyroid disorders during the COVID-19 pandemic. Patients with GD should not discontinue their drugs (ATDs); (2) treatment of patients with recently diagnosed GD who have not yet started therapy. ATD treatment since any relapse would require an urgent medical appointment and increase the risk of complications (e.g., thyroid storm), which can be triggered by infections such as COVID-19. In general, ATD treatment is maintained for 12–24 months, after which the medication can be suspended. Alternatively, prolonged use of low-dose ATDs may be considered since it is safe and may increase the chance of Graves’ Disease remission. During the COVID-19 pandemic, telemedicine may be an alternative to manage patients with COVID-19.

Our case report highlights the importance of educating patients with thyroid disorders during the COVID-19 pandemic. Patients with GD should not discontinue their drugs (ATDs); (2) treatment of patients with recently diagnosed GD who have not yet started therapy. ATD treatment since any relapse would require an urgent medical appointment and increase the risk of complications (e.g., thyroid storm), which can be triggered by infections such as COVID-19. In general, ATD treatment is maintained for 12–24 months, after which the medication can be suspended. Alternatively, prolonged use of low-dose ATDs may be considered since it is safe and may increase the chance of Graves’ Disease remission. During the COVID-19 pandemic, telemedicine may be an alternative to manage patients with COVID-19.

CONCLUSION

We have reported a fatal case of possible thyroid crisis induced by SARS-CoV-2 infection, which directly or indirectly destroys the thyroid follicles, triggering a thyroid crisis. Prompt and appropriate management and treatment can reduce the incidence of multi-organ failure and mortality due to thyroid crisis induced by SARS-CoV-2 infection. There is no difference in treating thyroid crises before and during a COVID-19 pandemic. Maintaining a
euthyroid state is very important to prevent the relapse of thyroid disease.

Acknowledgments

The authors would like to thank Dr. Muhammad Faruk for his assistance in language polishing and formatting of this case report.

Ethical Consideration

Patient consent was obtained from the relative submission of the manuscript.

Statement of Authorship

The authors certified fulfillment of ICMJE authorship criteria.

Author Contribution Statement

FH conceived the idea, validated research outputs, conducted investigation, provided study materials, curated the data, wrote the original draft preparation, reviewed and edited the manuscript, prepared data presentation, coordinated research activity planning, acquired financial support.

AMA conceived the idea, validated research outputs, conducted investigation, provided study materials, wrote the original draft preparation, reviewed and edited the manuscript, supervised the research activity planning.

HI conceived the idea, validated research outputs, conducted investigation, provided study materials, curated the data, wrote the original draft preparation, reviewed and edited the manuscript.

Author Disclosure

The authors declared no conflict of interest.

Funding Source

None.

References

1. Scappaticcio L, Pitoia F, Esposito K, Piccardo A, Trimboli P. Impact of COVID-19 on the thyroid gland: An update. Rev Endocr Metab Disord. 2021;22(4):803-15. PMID: 32341508. PMCID: PMC6788298. https://doi.org/10.1007/s11154-020-09615-z.

2. Inaba H, Azauwa T. Coronavirus disease 2019 and the thyroid - Progress and perspectives, Front Endocrinol (Lausanne). 2021;12:708333. PMID: 34276567. PMCID: PMC829745. https://doi.org/10.3389/ fendo.2021.708333.

3. McDougall, IR. Hyperthyroidism. In: McDougall IR, ed. Thyroid and perspectives, Front Endocrinol (Lausanne). 2021;12:708333. PMID: 34276567. PMCID: PMC829745. https://doi.org/10.3389/ fendo.2021.708333.

4. Satoh, Suzuki A, Wakino S, et al. 2016 Guidelines for the management of thyroid disorders. J Endocrinol Invest. 2021;44(9):1801-14. PMID: 33765282. PMCID: PMC7929516. https://doi.org/10.23501/jsei.2021.0153.e.

5. Pranaskati ME, Talirasa N, Rasena HA, Purwanto RY, Anwar SL. Thyrototoxicosis occurrence in SARS-CoV-2 infection: A case report. Am J Med Sci (Lon). 2022;375(10):IO10.1097/AMJ.0000000000002433. 2022;375(10):30700.

6. Akbarzadeh M, Mohammad-Salar H. Heparin-thromboembolic involvement in COVID-19 patients: A retrospective study. Cureus. 2020;12(9):e10333. PMID: 33052924. PMCID: PMC7546597. https://doi.org/10.7759/cureus.10333.

7. Ali A, Mostafa W, Fernandez C, Ahmad H, Htwe N. Apathetic thyroid storm with cardiorespiratory failure, pulmonary embolism, and coagulopathy in a young male with Graves’ Disease and myopathy. Case Rep Endocrinol. 2020;2020:8996777. PMID: 33029436. PMCID: PMC7530497. https://doi.org/10.1155/2020/8996777.

8. Al-Saadi A, El-Aouzi AN, D’Molim, fibrinogen, and IL-6 in COVID-19 patients with suspected venous thromboembolism: A narrative review. Vasc Health Risk Manag. 2020;16:455-62. PMID: 33223833. PMCID: PMC7672709. https://doi.org/10.2147/VHRM.S289862.

9. Asszter H, Ogawa H. COVID-19-associated coagulopathy and disseminated intravascular coagulation. Int J Hematol. 2021;113(1):45-57. PMID: 33161508. PMCID: PMC7648664. https://doi.org/10.1007/s12185-020-03029-y.

10. Lahav O, Tamir T. Evaluation of the Padua Prediction Score ability to predict venous thromboembolism in Israeli non-surgical hospitalized patients using electronic medical records, Sci Rep. 2022;12(1):16121. PMID: 35414101. PMCID: PMC9005505. https://doi.org/10.1038/s41598-020-22093-y.

11. Arpaia GG, Caleffi A, Marano G, et al. Padua prediction score and IMPROVE score do predict in-hospital mortality in Internal Medicine patients. Intern Emerg Med. 2020;15(6):997-1003. PMID: 31899205. PMCID: PMC7761993. https://doi.org/10.1007/s11739-019-02264-4.

12. Martins JRM, Villagelin DGP, Carvalho GA, et al.Sgarbi, Management of thyroid disorders during the COVID-19 outbreak: A position statement from the Thyroid Department of the Brazilian Society of Endocrinology and Metabolism (SBEM). Arch Endocrinol Metab. 2021;65(3):368-75. PMID: 33844898. https://doi.org/10.20945/2359-3990700000352.

13. Caron P. Thyroid disorders and SARS-CoV-2 infection: From pathophysiological mechanism to patient management. Ann Endocrinol (Paris). 2020;81(5):507-10. PMID: 32954066. PMCID: PMC7498405. https://doi.org/10.1016/j.ando.2020.09.001.